Taysha Gene Therapies, Inc. Cash Flow Statement
TSHA / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Taysha Gene Therapies, Inc. used $93M in operating cash flow and negative free cash flow of $94M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$109.0M | -$111.6M | -$166.0M | -$174.5M | -$174.5M | -$60.0M |
| Depreciation & Amortization | - | $1.4M | $1.2M | $492.0K | $492.0K | $9.0K |
| Operating Cash Flow | -$93.1M | -$73.0M | -$88.4M | -$117.0M | -$117.0M | -$30.7M |
| Capital Expenditures | $738.0K | $3.9M | $20.6M | $15.3M | $15.3M | $82.0K |
| Free Cash Flow | -$93.8M | -$76.9M | -$109.0M | -$132.3M | -$132.3M | -$30.8M |
| FCF Margin | -960.1% | -497.6% | -4356.9% | -5289.6% | - | - |